The results of a recent study show the PKG system detected 85% of Parkinson's patients previously considered "controlled" by their treating physician were, in fact, uncontrolled and experiencing treatable symptoms. The study also showed that without the PKG, one third of the patients that the PKG system detected as having treatable symptoms would have been missed by expert movement disorder specialists (MDS).1 When patients, who were classified as uncontrolled, were treated per their physicians' recommendations, their outcomes improved, including the subgroup where only the PKG, not the MDS, detected the need for treatment changes.1
GKC is currently conducting studies to establish the value of the PKG system in improving the entire advanced therapy pathway from more efficient referrals to better optimization on therapy. Early evidence suggests the PKG may enhance the DBS pathway, this research is ongoing.2
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About Global Kinetics Corporation (GKC) and the Parkinson's KinetiGraphTM System (PKGTM)
GKC, recognized as a Top 10 Most Innovative Health Company by the Fast Company Awards 2017, is a commercial-stage digital health company revolutionizing the management of Parkinson's.
The company's PKG System is a patient-friendly, algorithm-based system that records body movements and other symptoms over the course of many days and creates data-driven reports that empower more personalized treatment and management decisions—with the goal of leading to a higher quality of life for patients.
The PKG System continues to be accepted as a first line clinical system and is the only FDA-cleared and clinically validated digital health technology that can provide continuous and objective measurement of patients' symptoms in everyday environments. This includes the continuous and objective measure of bradykinesia (or slowness of movement), the most clinically important symptom of Parkinson's disease.
In addition to increased use in routine clinical care for Parkinson's disease, Global Kinetics continues to pursue partnerships with major pharmaceutical and medical technology to help measure the efficacy of new and advanced therapies, as well as use in clinical trials, telehealth, remote monitoring and other augmented platform opportunities.
SOURCE Global Kinetics Corporation
Back to HCB News
